PARP9 and myelodysplastic syndrome: As anticipated, compared to healthy volunteers, the expression levels of SREBF1, MAP3K11, PARP9, and PTPN6 were found to be upregulated, while the expression levels of EZH2 and MDM4 were downregulated in the MDS samples (Figure 8).